Bank of New York Mellon’s Satsuma Pharmaceuticals, Inc. Common Stock STSA Stock Holding History

Bank of New York Mellon’s Portfolio STSA Stock Details STSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-16,262	Closed	-$98K	–	4582
2022 Q3	$98K	Buy	+16,262	New	+$92.2K	﹤0.01%	4201
2021 Q2	–	Sell	-39,472	Closed	-$234K	–	4501
2021 Q1	$234K	Buy	39,472 +8,610	+28%	+$52.2K	﹤0.01%	4005
2020 Q4	$143K	Buy	30,862 +5,746	+23%	+$24.8K	﹤0.01%	4034
2020 Q3	$97K	Sell	25,116 -2,246	-8%	-$45.1K	﹤0.01%	3957
2020 Q2	$786K	Buy	27,362 +11,580	+73%	+$268K	﹤0.01%	3238
2020 Q1	$340K	Buy	+15,782	New	+$358K	﹤0.01%	3550

Other funds holding STSA

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NFGH

Nan Fung Group Holdings Kai Tak, Hong Kong $121M AUM 56.89% 1-Year Est. Return

Bank of New York Mellon's STSA Position: Q4 2022 in Review

Bank of New York Mellon sold out of Satsuma Pharmaceuticals, Inc. Common Stock (STSA) in Q4 2022, closing a stake of 16,262 shares — an estimated $98K sold.

Bank of New York Mellon first reported a position in STSA in Q1 2020 and held it in 6 quarters. The position peaked at $786K in Q2 2020. 33 funds tracked by Wall St. Rank hold STSA as of Q4 2022.

Bank of New York Mellon reported no remaining Satsuma Pharmaceuticals, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
Bank of New York Mellon sold 16,262 Satsuma Pharmaceuticals, Inc. Common Stock shares in Q4 2022, an estimated $98K.
Bank of New York Mellon first reported a position in Satsuma Pharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 6 quarters.
Bank of New York Mellon's Satsuma Pharmaceuticals, Inc. Common Stock position peaked at $786K in Q2 2020.
33 funds tracked by Wall St. Rank held Satsuma Pharmaceuticals, Inc. Common Stock as of Q4 2022.

Based on Bank of New York Mellon's 13F filing for Q4 2022, filed 14 Feb 2023.